Optimizing Treatment for Patients with Relapsed/Refractory Multiple Myeloma : Episode 2

Navigating Treatment Advancements and Recent Approvals in R/R Multiple Myeloma: Expert Insights

June 28, 2024

By Rafael Fonseca, MD
Samer A. Al'Hadidi, MD

Opinion

Video

Focusing on recent approvals in earlier lines of relapsed/refractory multiple myeloma, the panel has a comprehensive discussion on the CARTITUDE-4 and KarMMa-3 studies and shares clinical insights on administering CAR T-cell therapy and monitoring patients.

EP: 1.Advancements in the Treatment of Newly Diagnosed MM: Updates from the Phase 3 IMROZ Study

Now Viewing

EP: 2.Navigating Treatment Advancements and Recent Approvals in R/R Multiple Myeloma: Expert Insights

EP: 3.Updates From the Phase 2 MonumenTAL-2 Study Investigating Talquetamab in R/R MM

EP: 4.Long-Term Follow-up with Teclistamab in R/R MM: Updates from MajesTEC-1

EP: 5.Treatment Strategies with Elranatamab in R/R MM: Updates from the MagnetisMM Trials

EP: 6.Expert Perspectives: Sequencing Approaches with CAR-T and Bispecifics in R/R MM

EP: 7.Expert Insights: Strategies for Step-Up Dosing and Long-Term Treatment Management with Bispecifics in R/R MM

EP: 8.The Role of MRD Testing in Guiding Treatment in R/R MM: ASCO 2024 Updates from PERSEUS

EP: 9.Considerations in Sequencing BCMA-Targeting Bispecifics and CAR-T Therapies in R/R MM

EP: 10.Cilta-cel in R/R MM: ASCO 2024 Updates from CARTITUDE Trials

EP: 11.AE Management for CAR-T Therapy: Expert Insights and Perspectives

EP: 12.Looking Ahead: ASCO 2024 Updates and Future Perspectives

EP: 13.Key Takeaways and Clinical Pearls on the Treatment of R/R MM in the Era of Bispecifics

EP: 14.Bispecific Antibodies Are Taking the Multiple Myeloma World by Storm

Video content above is prompted by the following question(s):

Focusing on recent approvals in earlier lines of therapy in relapsed/refractory multiple myeloma, discuss the CARTITUDE-4 and KarMMa-3 studies.

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!